{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '3.', 'STUDY SCHEMATICS AND SCHEDULE OF ASSESSMENTS AND DOSING FOR', 'STUDY KCP-330-023', 'Table 2: Schedule of Assessments for Study KCP-330-023', 'Screeningb', 'C1', 'C1', 'MM Disease', 'In-clinic Dosing', 'EoT', 'Safety', 'Durability of', 'Phone Call', 'Assessment', 'Visits', 'Visit', 'Follow-', 'Response and', 'Visits', '(> C1D2)', 'up Call', 'Survival', '(Table 13)', '(Table 13)', 'Follow-up', 'Visit', 'D -28 to -1', 'D1', 'D3', 'See Table 4,', 'See Table 4,', '14', '30 days', 'Every', '(selinexor-', 'Table 5,', 'Table 5,', 'Days', 'after last', '3 months', 'containing', 'Table 6, and', 'Table 6, and', 'Post-', 'dose of', 'until', 'regimens', 'Table 7', 'Table 7', 'Last', 'treatment', 'End-of-Study', 'only)', 'Dose', 'Section 11.7.4', 'Activity/Assessment', 'Section', '2 days', '2 days', '+ 7 days', '14 days', 'ICF', '11.1', 'X', 'Patient History', 'Inclusion/Exclusion', '7.2/7.3', 'X', 'Demographics', '11.2.1', 'X', 'Medical History', '11.2.2', 'X', 'Clinical Assessments', 'Height', '11.5.1.1', 'X', 'Xi', 'Weight', '11.5.1.1', 'X', 'X', '(D1 of each', 'X', 'cycle only)', 'BSAj', '11.5.1.1', 'X', 'X', 'Vital signsk', '11.5.1.2', 'X', 'X', 'X\u00b9', 'X', 'X', 'Complete PE', '11.5.1.2', 'X', 'X', 'Perform if', 'Perform if', 'Symptom-directed', '11.5.1.2', 'PE', 'clinically', 'Perform if clinically indicated', 'clinically', 'indicated', 'indicated', 'X', 'ECOG', '11.5.1.2', 'X', '(D1 of each', 'X', 'cycle only)', 'Confidential', 'Page 22', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Screeningb', 'C1', 'C1', 'MM Disease', 'In-clinic Dosing', 'EoT', 'Safety', 'Durability of', 'Phone Call', 'Assessment', 'Visits', 'Visit', 'Follow-', 'Response and', 'Visits', '(> C1D2)', 'up Call', 'Survival', '(Table 13)', '(Table 13)', 'Follow-up', 'Visit', 'D-28 to -1', 'D1e', 'D3f', 'See Table 4,', 'See Table 4,', '14', '30 days', 'Every', '(selinexor-', 'Table 5,', 'Table 5,', 'Days', 'after last', '3 months', 'containing', 'Table 6, and', 'Table 6, and', 'Post-', 'dose of', 'until', 'regimens', 'Table 7', 'Table 7', 'Last', 'treatment', 'End-of-Study', 'only)', 'Dose', 'Section 11.7.4', 'Activity/Assessment', 'Section', '2 days', '2 days', '+ 7 days', '14 days', 'Ophthalmic', '11.5.1.4', 'Xm', 'Perform if clinically indicated', 'X', 'examination', '12-lead ECG\"', '11.5.1.3', 'Xm', 'Perform if clinically indicated', 'X', 'Laboratory Assessments', \"May be performed more frequently if clinically indicated, or at the Investigator's discretion\", 'Urinalysis', '11.5.2.1', 'Xm', 'X', 'CBC with', 'X', '11.5.2.1', 'X\u00b0', 'X', 'X', 'differential', '(C1D8 only)', 'Complete serum', 'X', '11.5.2.1', 'X', 'X', 'X', 'X', 'chemistry', '(C1D8 only)', 'Coagulation tests', '11.5.2.1', 'Xm', 'X', 'X', 'Pregnancy test (if', '11.5.2.2', 'X', '(D1 of each', 'X', 'applicable)P', 'cycle only)', 'C-reactive protein', '11.7.1', 'Xm', 'X', 'PK at Selected Investigational Sites (up to 25 patients per arm)', 'Vd Arm subset:', 'Blood draws for', 'X', '11.4', 'bortezomib PK', '(C2D11 only)', 'testing', 'SVd Arm subset:', 'Blood draws for', 'X', '11.4', 'bortezomib and', '(C2D15 only)', 'selinexor PK testing', 'Confidential', 'Page 23', 'Version 4.0']\n\n###\n\n", "completion": "END"}